Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616000593437
Ethics application status
Approved
Date submitted
12/04/2016
Date registered
6/05/2016
Date last updated
6/05/2016
Type of registration
Retrospectively registered

Titles & IDs
Public title
Uptake kinetics of dietary phenylalanine during continuous enteral feeding
Scientific title
Uptake kinetics of dietary 13C-phenylalanine during continuous enteral feeding in healthy subjects
Secondary ID [1] 288978 0
none
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Enteral feeding 298371 0
Condition category
Condition code
Diet and Nutrition 298475 298475 0 0
Other diet and nutrition disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
During development of a methodology for studying enteral nutrition in ICU patients (see trial ID ACTRN12614000476639) we studied a pilot group of ICU patients to determine uptake kinetics of dietary stable-isotope-labeled phenylalanine during continuous enteral feeding. Relevant findings were a high inter-individual variability of 13C-phenylalanine plasma enrichment and uncertain steady state condition after 6 hrs of feeding (unpublished data).

The objective of the current trial is to determine whether a steady state of 13C-phenylalanine isotopic enrichment in plasma is reached after 6, 8, 10 or 12 hrs of 13-C-phenylalanine administration simultaneous with continuous enteral feeding. Subjects are admitted on the evening before the tracer study and stay under observation throughout the experiment. A nasogastric feeding tube is placed and a continuous infusion of a commercially available complete nutrition formula, Fresubin (registered trademark) Original, is started at a dose corresponding to 100% of estimated energy requirement. After a 12 hr equilibration period, a cannula for blood sampling is placed in an artery. Ongoing continuous nutrition is supplemented with a continuous infusion of 13C-labeled phenylalanine for another 12 hrs. The 13C-phenylalanine dose is calculated to yield an isotopic enrichment of 30.8% of the total dietary phenylalanine content, i.e. feeding formula + tracer Blood samples are taken every 30 minutes for the remaining 12 hrs. Isotopic enrichment of 13C-phenylalanine in plasma is measured by gas chromatography-mass spectrometry.
Intervention code [1] 294464 0
Treatment: Other
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 297963 0
Plasma enrichment of 13C-phenylalanine
Timepoint [1] 297963 0
Every 30 minutes from 12 to 24 hours post commencement of continuous enteral feeding
Secondary outcome [1] 322777 0
None
Timepoint [1] 322777 0
None

Eligibility
Key inclusion criteria
Healthy adults
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Nutritional/metabolic disease, serious organ dysfunction

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Pharmacokinetics
Statistical methods / analysis
Results are analysed both per individual and for pooled data from the whole cohort. The primary question is whether isotopic enrichement of 13C-Phe reaches a steady state. This can be analysed by linear regression over a set of timepoints to determine whether there is a gradient over time that is significantly different from zero.

A sample size calculation is not made because the effect size is not known and can not be estimated with sufficient reliability from existing data.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
Actual
24/04/2016
Date of last participant enrolment
Anticipated
30/05/2016
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
10
Accrual to date
Final
Recruitment outside Australia
Country [1] 7804 0
Sweden
State/province [1] 7804 0

Funding & Sponsors
Funding source category [1] 293334 0
Government body
Name [1] 293334 0
Regional Agreement on Medical Training and Clinical Research (ALF) between Stockholm County Council and Karolinska Institutet
Country [1] 293334 0
Sweden
Primary sponsor type
Individual
Name
Prof Olav Rooyackers
Address
Karolinska Institutet
Inst. for klinisk vetenskap, intervention och teknik
Enheten for anestesi
Karolinska Universitetssjukhuset, Huddinge, K32
141 86 Stockholm
Country
Sweden
Secondary sponsor category [1] 292153 0
None
Name [1] 292153 0
Address [1] 292153 0
Country [1] 292153 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 294803 0
Regionala etikprovningsnamnden i Stockholm
Ethics committee address [1] 294803 0
Ethics committee country [1] 294803 0
Sweden
Date submitted for ethics approval [1] 294803 0
30/04/2014
Approval date [1] 294803 0
17/02/2016
Ethics approval number [1] 294803 0
2016/76-31/4

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 53742 0
Prof Olav Rooyackers
Address 53742 0
Karolinska Institutet Inst. for klinisk vetenskap, intervention och teknik Enheten for anestesi Karolinska Universitetssjukhuset, Huddinge, K32 141 86 Stockholm
Country 53742 0
Sweden
Phone 53742 0
+46-8-58580553
Fax 53742 0
Email 53742 0
olav.rooyackers@ki.se
Contact person for public queries
Name 53743 0
Olav Rooyackers
Address 53743 0
Karolinska Institutet Inst. for klinisk vetenskap, intervention och teknik Enheten for anestesi Karolinska Universitetssjukhuset, Huddinge, K32 141 86 Stockholm
Country 53743 0
Sweden
Phone 53743 0
+46-8-58580553
Fax 53743 0
Email 53743 0
olav.rooyackers@ki.se
Contact person for scientific queries
Name 53744 0
Olav Rooyackers
Address 53744 0
Inst. for klinisk vetenskap, intervention och teknik Enheten for anestesi Karolinska Universitetssjukhuset, Huddinge, K32 141 86 Stockholm
Country 53744 0
Sweden
Phone 53744 0
+46-8-58580553
Fax 53744 0
Email 53744 0
olav.rooyackers@ki.se

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Study results articleYes https://www.clinicalnutritionjournal.com/article/S... [More Details]

Documents added automatically
No additional documents have been identified.